ORTIN GLOBAL LIMITED Stock Price Today (NSE: ORTINGLOBE)
Fundamental Score
ORTIN GLOBAL LIMITED Share Price — Live NSE/BSE Price, Fundamentals & Analysis
ORTIN GLOBAL LIMITED share price today is ₹17.25, up +3.79% on NSE/BSE as of 16 September 2026. ORTIN GLOBAL LIMITED (ORTINGLOBE) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹14.03 (Cr). The 52-week high for ORTINGLOBE share price is ₹21.30 and the 52-week low is ₹10.66. The company has a Return on Equity (ROE) of -46.06% and a debt-to-equity ratio of 0.81.
ORTIN GLOBAL LIMITED Share Price Chart — NSE/BSE Historical Performance
ORTIN GLOBAL LIMITED share price chart: 6.15% return over the past month. 52-week high ₹21.30, 52-week low ₹10.66.
ORTIN GLOBAL LIMITED — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹16.63 | ₹17.38 | ₹16.01 | ₹17.25 | 11.64K (Cr) | |
| ₹17.50 | ₹17.58 | ₹16.62 | ₹16.62 | 17.18K (Cr) | |
| ₹16.70 | ₹17.11 | ₹15.81 | ₹17.09 | 30.39K (Cr) | |
| ₹15.50 | ₹16.30 | ₹15.22 | ₹16.30 | 31.45K (Cr) | |
| ₹15.54 | ₹16.29 | ₹15.53 | ₹15.53 | 2.93K (Cr) | |
| ₹16.20 | ₹16.20 | ₹15.32 | ₹15.93 | 57.53K (Cr) | |
| ₹15.82 | ₹15.89 | ₹15.26 | ₹15.44 | 5.14K (Cr) | |
| ₹15.70 | ₹15.77 | ₹15.20 | ₹15.67 | 9.74K (Cr) | |
| ₹15.05 | ₹15.77 | ₹15.00 | ₹15.02 | 2.60K (Cr) | |
| ₹15.36 | ₹15.86 | ₹15.36 | ₹15.43 | 2.95K (Cr) |
ORTIN GLOBAL LIMITED — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹15.34 | ₹17.58 | ₹14.80 | ₹17.25 | +12.45% | |
| ₹14.60 | ₹16.50 | ₹14.40 | ₹15.30 | +4.79% | |
| ₹17.00 | ₹17.89 | ₹14.00 | ₹15.35 | -9.71% | |
| ₹16.20 | ₹21.30 | ₹14.96 | ₹17.54 | +8.27% | |
| ₹15.50 | ₹17.12 | ₹13.50 | ₹15.51 | +0.06% | |
| ₹14.23 | ₹16.19 | ₹13.62 | ₹15.50 | +8.92% | |
| ₹17.30 | ₹17.40 | ₹13.50 | ₹13.56 | -21.62% | |
| ₹12.98 | ₹19.90 | ₹11.51 | ₹17.19 | +32.43% | |
| ₹13.80 | ₹14.35 | ₹11.90 | ₹12.47 | -9.64% | |
| ₹11.85 | ₹17.46 | ₹11.65 | ₹13.81 | +16.54% | |
| ₹10.91 | ₹12.89 | ₹10.83 | ₹11.96 | +9.62% | |
| ₹11.42 | ₹12.89 | ₹10.66 | ₹11.25 | -1.49% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
ORTIN GLOBAL LIMITED Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
ORTIN GLOBAL LIMITED Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ORTINGLOBE across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (92.65%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Healthy Liquidity Position (Current Ratio: 2.15)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
11 factors identified
Below-Average Return on Equity (-46.06%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-32.27%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-315.17%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
High Price-to-Book Ratio (7.09x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Revenue Contraction (-70.85%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-58.50% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (-327.82x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-3.99 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (1.23%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Limited Institutional Interest (FII+DII: 1.68%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
ORTIN GLOBAL LIMITED vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare ORTIN GLOBAL LIMITED with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
ORTIN GLOBAL LIMITEDORTIN GLOBAL LI...Selected✓ ORTINGLOBE • 539287 | 16.6/100 | ₹17.25₹17 | ₹14.03₹14.03 | — — | -46.06%Poor -46.06% Poor | -32.27%Poor -32.27% Poor | 0.81Good 0.8 Good | — — | -58.50%Poor -58.50% Poor | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
ORTIN GLOBAL LIMITED Quarterly Performance
Latest quarterly metrics for ORTINGLOBE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-70.85%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
92.65%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-58.50%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
ORTIN GLOBAL LIMITED Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ORTINGLOBE — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
ORTIN GLOBAL LIMITED Financial Statements
Annual income statement, balance sheet and cash flow for ORTIN GLOBAL LIMITED (ORTINGLOBE) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for ORTIN GLOBAL LIMITED
About ORTINGLOBE (ORTIN GLOBAL LIMITED)
Ortin Global Ltd is a pioneering pharmaceutical company dedicated to the advancement of healthcare through the development, production, and distribution of high-quality medicines. ...With a firm commitment to innovation and patient well-being, Ortin Global strives to address unmet medical needs across a spectrum of therapeutic areas. Driven by a team of experienced scientists and professionals, the company focuses on creating effective and accessible pharmaceutical solutions, while upholding the highest standards of quality and ethical conduct. Ortin Global envisions a world where advanced healthcare is readily available to all, and it pursues this goal with unwavering dedication and a spirit of continuous improvement. Ortin Global’s core business revolves around the creation and manufacturing of a diverse portfolio of pharmaceutical formulations, encompassing a wide range of therapeutic categories. The company produces tablets, capsules, syrups, and dry powders, each meticulously crafted to meet stringent quality control standards. Ortin Global's product offerings include medications for managing chronic conditions like diabetes, allergies, and cardiovascular ailments, as well as treatments for infectious diseases, pain relief, and mental health. The company's commitment to innovation extends to constantly exploring new drug delivery systems and formulations that enhance patient compliance and improve therapeutic outcomes. Ortin Global is deeply rooted in a culture of quality, safety, and ethical business practices. The company adheres to the highest global regulatory standards and maintains state-of-the-art manufacturing facilities to ensure the purity, potency, and efficacy of its products. With a firm belief in corporate social responsibility, Ortin Global actively engages in initiatives that promote health awareness, environmental sustainability, and community development. As a trusted pharmaceutical company, Ortin Global remains steadfast in its mission to provide innovative and affordable healthcare solutions, enriching the lives of patients around the globe.
Company Details
Key Leadership
ORTINGLOBE Share Price: Frequently Asked Questions
What is the current share price of ORTIN GLOBAL LIMITED?
ORTIN GLOBAL LIMITED (ORTINGLOBE) trades at ₹17.25 on NSE and BSE. Market cap ₹14.03 (Cr). Educational data only.
What is the P/E ratio of ORTIN GLOBAL LIMITED?
ORTIN GLOBAL LIMITED has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for ORTIN GLOBAL LIMITED?
ORTIN GLOBAL LIMITED has a Bull Run score of 16.6/100 based on 25+ financial parameters.
Does ORTIN GLOBAL LIMITED pay dividends?
ORTIN GLOBAL LIMITED has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of ORTIN GLOBAL LIMITED?
ORTIN GLOBAL LIMITED has ROE of -46.06%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of ORTIN GLOBAL LIMITED?
ORTIN GLOBAL LIMITED has debt-to-equity of 0.81.
Is ORTIN GLOBAL LIMITED a good investment?
Bull Run gives ORTIN GLOBAL LIMITED a score of 16.6/100. This is not investment advice — consult a SEBI-registered advisor.